Deltanoid Pharmaceuticals is a drug development company

involved in breakthrough treatments for osteoporosis, renal

osteodystrophy, psoriasis and other disease targets.  The company

specializes in designing advanced vitamin D analogs, and several

of its vitamin D-based therapies are already being tested in

human clinical trials.  Deltanoid will develop therapies through

early stage human trials and will then seek partners to conduct

later stage human trials and commercialize the products.